Journals / Çukurova Üniversitesi Tıp Fakültesi Dergisi / 2016 / Cilt: 41 - Sayı: 1

Kronik hastalığı olan hastaların sigara ve Maraş otu kullanımı konusunda bilgi tutum ve davranışları

Knowledge, attitudes and behaviors of patients with chronic diseases about smoking and use of Maras powder

Pages
121–128
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Obtained findings revealed that smoking and use of Maras powder were quite common among chronic disease patients who need to be free from tobacco products use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: This study aims to find out the frequency of smoking and use of Maras powder, which are commonly used in our region, among patients with chronic disease and evaluate knowledge, attitudes and behaviors of patients with chronic disease about smoking and use of Maras powder.
📊
Key Findings & Data:Material and Methods:A total of 859 patients with a chronic disease admitted to 12 Family Health Centers in Kahramanmaras were included in the study.
💡
Conclusion & Impact:Conclusion: Obtained findings revealed that smoking and use of Maras powder were quite common among chronic disease patients who need to be free from tobacco products use.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: This study aims to find out the frequency of smoking and use of Maras powder, which are commonly used in our region, among patients with chronic disease and evaluate knowledge, attitudes and behaviors of patients with chronic disease about smoking and use of Maras powder. Material and Methods:A total of 859 patients with a chronic disease admitted to 12 Family Health Centers in Kahramanmaras were included in the study. Hypertension, diabetes mellitus, chronic renal failure, asthma, and heart diseases were among included chronic disease. There were 15 questions used to evaluate knowledge of smoking. Results: Ages of participants ranged between 18 and 86 years, with a mean age of 45.7±14.1 years (min.=18, max.=86). Among 859 participants 481 (56.0%) were male and 378 (44.0%) were female. Two-hundred and nine patients (24.3%) were regular smokers, 24 patients (2.8%) were occasional smokers, 222 patients (25.8%) were exsmokers and 404 patients (47.0%) were never smokers. 81 patients (9.4%) were using Maras powder and 18 patients (2.1%) were both smoking and using Maras powder. There was not a significant relation between smoking and Maras powder use. Conclusion: Obtained findings revealed that smoking and use of Maras powder were quite common among chronic disease patients who need to be free from tobacco products use. Furthermore, knowledge, attitudes and behaviors of these patients were detected to be insufficient.

Özet

Giriş: Bu çalışmada bölğemizde yaygın olarak kullanılan sigara ve Maraş otunun kronik hastalığı olan hastalarda kullanım sıklığı ile kullanıcıların bilgi, tutum ve davranışlarının değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmaya Kahramanmaraş ilindeki 12 aile sağlığı merkezine başvuran hastalardan kronik hastalığı olan 859 hasta dahil edildi. Hipertansiyon, diyabetes mellitus, kronik böbrek yetmezliği, astım ve kalp hastalığı kronik hastalık olarak kabul edildi. Katılımcıların sigara konusunda bilgi durumu 15 soru ile degerlendirildi. Bulgular: Katılımcıların yaş ortalaması 45.7±14.1 (min.=18, maks.=86) idi. Çalışmaya katılan 859 olgunun 481'i (%56.0) erkek, 378'i (%44.0) kadın idi. Katılımcıların 209'u (%24.3) düzenli, 24'ü (%2.8) ise ara sıra sigara kullandığını, 222'si (%25.8) sigara içmeyi bıraktığını ve 404'ü (%47.0) hayatında hiç sigara içmediğini belirtti. Hastaların 81'i (%9.4) Maraş otu, 18'i (%2.1) ise hem sigara hemde Maraş otu kullanmaktaydı. Sigara kullanımı ile Maraş otu kullanımı arasında anlamlı bir ilişki yoktu. Sigaranın zararları konusunda bilgi skoru ortalaması sigara içen grupta 11.5±2.4, sigara içmeyen grupta ise 11.7±2.4 olarak tespit edildi. Sonuç: kullanmamaları gereken kronik hastalığı olan hastaların sigara ve Maraş otunu önemli oranlarda kullandıkları ve bu maddeler konusunda bilgi tutum ve davranışlarının yetersiz olduğunu belirledik.

🔖

Cite This Article

ÇELİK, M., ERSOY, Ö., ÜCER, H., IŞIK, O., KETEN, H. S. (2022). Kronik hastalığı olan hastaların sigara ve Maraş otu kullanımı konusunda bilgi tutum ve davranışları. Çukurova Üniversitesi Tıp Fakültesi Dergisi, Cilt: 41 - Sayı: 1, 121–128. https://ajindex.com/articles/486036

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bartecchi CE, MacKenzie TD, Robert W: The human costs of tobacco use. Schrie. N Engl J Med. 1994;330:907-12.
  2. Beyer J, Waverly I. Tobacco control policy. Strategies, successes and setbacks. The World Bank. 2003;1-12. WHO. WHO Report on the Global Tobacco Epidemic, 2009: Implementing Smoke-free Environments. Geneva, World Health Organization, 2009.
  3. Mackay J, Eriksen M. The Tobacco Atlas. Geneva, World Health Organization, 2002.
  4. Elmalı F, Günay O, Çıtıl R, Öztürk Y. Diyabetik hastalarda tıbbi ve sosyal faktörlerin yaşam kalitesine etkisi. Erciyes Medical Journal. 2010;32:253-64.
  5. İnan A, Yılmazkaya Y. Astma, aşırı bronşial cevap ve düşük FEV1 ile kronik öksürük ve sigara arasındaki ilişki. Solunum. 1995;19:140-6.
  6. Sucakli MH, Ozkan F, Inci MF, Celik M, Keten HS, Bozoglan O. Effects of smokeless tobacco (Maras powder) use on carotid intima media thickness. Med Sci Monit. 2013;19:859-64.
  7. Aral M, Ekerbicer H, Celik M, Ciragil P, Gul M. Comparison of effects of smoking and smokeless tobacco "Maras powder" use on humoral immune system 2006;3:85019. Mediators Inflamm. Kafas A: Analysis of factors affecting cigarete smoking and Maras powder use among adults in the urban area of Kahramanmaras (Master's thesis). Kahramanmaraş, Kahramanmaras Sutcu Imam University, Turkey, 2011, WHO. WHO guidelines for controlling and monitoring the tobacco epidemic. Geneva, World Health Organization, 1998.
  8. Kozan Ö, Özcan EE, Sancaktar O, Kabakcı G. The prevalence of microalbuminuria and relevant cardiovascular risk factors in Turkish hypertensive patients. Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol. 2011;39:635-45.
  9. Chen R, Song Y, Hu Z, Brunner EJ. Predictors of diabetes in older people in urban China. PLoS ONE. 2012;7:e50957. Ayah R, Joshi MD, Wanjiru R, Njau EK, Otieno CF, Njeru EK, Mutai KK. A population-based survey of prevalence of diabetes and correlates in an urban slum community in Nairobi, Kenya. BMC Public Health. 2013;13:371. Thomsen RW, Nielsen JS, Ulrichsen SP, Pedersen L, Hansen AMS, Nilsson T. The Danish centre for strategic research in type 2 diabetes (DD2) study: Collection of baseline data from the first 580 patients. Clin Epidemiol. 2012;4:43-8.
  10. Agborsangaya CB, Gee ME, Johnson ST, Dunbar P, Langlois MF, Leiter LA et al. Determinants of lifestyle behavior in type 2 diabetes: Results of the 2011 cross-sectional survey on living with chronic diseases in Canada. BMC Public Health. 2013;13:451. Funakoshi Y, Omori H, Onoue A, Mihara S, Ogata Y, Katoh T. Association be